Company News
Axsome Therapeutics FDA Approval for Alzheimer’s Agitation
Axsome Therapeutics shares jumped about 14% after the FDA approved AUVELITY for agitation in Alzheimer’s disease patients.
AUVELITY, already approved for major depressive disorder, received Breakthrou
